Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2014

Tang Chad, Hess Kenneth, Jardim Denis Leonardo F, Gagliato Debora De Melo, Tsimberidou Apostolia M, Falchook Gerald, Fu Siqing, Janku Filip, Naing Aung, Piha-Paul Sarina, Subbiah Vivek, Wheler Jennifer, Zinner Ralph G, Kurzrock Razelle, Ellis Lee M, Meric-Berstam Funda, Hong David S

Abstract excerpt

PURPOSE: We hypothesized that chemotherapy synergizes with VEGF/VEGFR (VEGF/R) inhibitors in patients with advanced solid malignancies. EXPERIMENTAL DESIGN: Patients treated on phase I protocols between December 2004 and July 2013 (n = 1,498) were included in this analysis. The primary outcome was clinical benefit, defined as stable disease ≥ 6 months, complete response, or partial response. Two odds ratios (OR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Neoplasms

Share to Odds Ratio

Share to Protein Kinase Inhibitors

Share to Receptors, Vascular Endothelial Growth Factor

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 25316815
DOI: 10.1158/1078-0432.CCR-14-1582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.PMID 25316815Read ↗

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.Semantic proximity Read ↗

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentSemantic proximity Read ↗

Effect of Antiangiogenic-Based Treatment and Systemic Inflammatory Factors on Outcomes in Patients With BRAF v600-Mutated Metastatic Colorectal Cancer: A Real-World Study in SpainSemantic proximity Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Semantic proximity Read ↗

Effective Suppression of Hypoxia Induced Angiogenesis by Synergism of Simvastatin and Metformin via Inhibiting ET-1-ETBR-Hif1α Signaling AxisSemantic proximity Read ↗

Quercetin Synergistically Potentiates the Anti-Angiogenic Effect of 5- Fluorouracil on HUVEC Cell LineSemantic proximity Read ↗

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled AnalysisSemantic proximity Read ↗

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulationSemantic proximity Read ↗

Synergistic effects of anlotinib and DDP synergy in breast cancer treatment: inhibiting of cell growth and migration, and augmenting apoptosis and autophagy via modulation of the VEGF/JAK2/STAT3 axisSemantic proximity Read ↗

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.Semantic proximity Read ↗

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.